A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1

Christine ArmbrusterHermann Katinger


To study the safety, immunogenicity and pharmacokinetics of two intravenously administered human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 in humans. Open label clinical phase I trial. Primary institutional care. Seven HIV-1-infected healthy volunteers with > or = 500 x 10(6)CD4 cells/l and < or = 10,000 HIV-1 RNA copies/ml, not treated with highly active antiretroviral therapy (HAART), entered and finished the study. and main outcome measures: Eight separate infusions of the hMAb were administered over a 4-week period (total dose 14 g). The safety was assessed by physical examination, blood chemistry, complete blood cell count and recording adverse events. 2F5 and 2G12 plasma levels were determined prior to and at the end of each infusion and during the follow-up period of 22 weeks. No clinical or laboratory abnormalities were observed throughout the study. The median distribution half-life (t(1/2 alpha)) of 2F5 and 2G12 was 1.02 (range, 0.77-1.47) days and 2.49 (range, 0.92-4.59) days, respectively. The elimination half-life (t(1/2 beta)) was calculated to be 7.94 (range, 3.46-8.31) days for 2F5 and 16.48 (range, 12.84-24.85) days for 2G12. The median plasma concentration immediately after the first infusion was 21...Continue Reading

Associated Clinical Trials


Jan 10, 1995·Virology·Q J SattentauP Poignard
Dec 1, 1994·AIDS Research and Human Retroviruses·M PurtscherA Jungbauer
Aug 1, 1993·The Journal of Infectious Diseases·J M JacobsonA M Prince
Jun 1, 1996·Clinical Pharmacology and Therapeutics·E J WolfeJ G Gambertoglio
Jun 24, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·T R O'BrienJ J Goedert
Jul 11, 2000·Nature Medicine·D D Ho, L Zhang

❮ Previous
Next ❯


Feb 8, 2007·Transgenic Research·Penelope Amelia Claire SparrowJulian K C Ma
Jun 14, 2005·Immunology Letters·Xiao-Nan DongYing-Hua Chen
Jun 29, 2002·Current Opinion in Immunology·Flavia Ferrantelli, Ruth M Ruprecht
Apr 19, 2005·Nature Biotechnology·Jianmin FangKarin Jooss
Nov 1, 2007·Journal of Applied Animal Welfare Science : JAAWS·Andrew Knight
Aug 11, 2011·AIDS Research and Human Retroviruses·Weizao Chen, Dimiter S Dimitrov
Apr 3, 2009·Current Opinion in HIV and AIDS·Weizao Chen, Dimiter S Dimitrov
Nov 18, 2009·Current Opinion in Infectious Diseases·Georgina C Morris, Charles J N Lacey
Nov 2, 2012·Clinical and Vaccine Immunology : CVI·Vincent J VendittoFrancis C Szoka
Jan 8, 2013·BMC Medicine·Michela FlegoStefano Vella
Dec 29, 2010·PLoS Pathogens·Xin M LuoDavid Baltimore
Apr 3, 2012·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Rui GongDimiter S Dimitrov
Apr 20, 2014·BioMed Research International·Matilde MerlinLinda Avesani
May 7, 2014·Immunology and Cell Biology·Wendy R WinnallStephen J Kent
May 24, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ming SunDavid D Ho
Jan 15, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jeffrey T SafritUNKNOWN Ghent IAS Working Group on HIV in Women Children
Jul 20, 2005·Expert Review of Vaccines·Aldar S Bourinbaiar, Rivka Abulafia-Lapid
Aug 2, 2002·Expert Opinion on Investigational Drugs·Christine Armbruster
Dec 13, 2006·Expert Opinion on Investigational Drugs·Paola Citterio, Stefano Rusconi
Oct 2, 2003·Expert Opinion on Biological Therapy·L H Stockwin, S Holmes
Mar 10, 2004·Expert Opinion on Biological Therapy·Maja A SommerfeltBirger Sørensen
Feb 24, 2009·Annals of Medicine·Haritha SamaranayakeSeppo Ylä-Herttuala
Feb 5, 2016·Current HIV/AIDS Reports·Kathryn E Stephenson, Dan H Barouch
Nov 9, 2010·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Ryan J MorrowR Karl Malcolm
Dec 25, 2015·Science Translational Medicine·Rebecca M LynchUNKNOWN VRC 601 Study Team
Dec 24, 2005·Enfermedades infecciosas y microbiología clínica·Felipe GarcíaPere Domingo

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.